Industry mutes doctors

Share this article:

Drugmakers are paying less to get doctors talking, reports ProPublica, which has found the the industry has slashed the amount of money it spends on speakers' fees.

As examples, the nonprofit notes that Eli Lilly spent 55% less on speakers in 2012 than it did in 2011, Pfizer spent 62% less and Novartis whittled its speaker spend by 40%. In terms of numbers, this comes down to Lilly spending $21.6 million in 2012, compared to $47.9 million three years ago, while Pfizer dropped only $8.3 million on speakers in 2012, compared to $22 million in 2011.

ProPublica notes that not all companies have reduced their spend and that some companies attributed their reduced speakers' budgets to lack of pipeline excitement as opposed to fear of Sunshine Act disclosures.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.